AC
Aisling Capital Management LP
13F filer · CIK 0001766721Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$472MU.S. long equity reported on 13F
Positions141 new · 0 closed
Net flow last quarter-$35.4MBuys minus sells
Top 10 positions weight99.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 13, 202614 positions | |||||
| $342M | 72.48% | 2.35% | -9.8% | Q2 2019 | |
| $37.6M | 7.98% | 1.83% | Not reported | Q2 2021 | |
| $28.8M | 6.10% | 1.48% | Not reported | Q1 2020 | |
| $20.3M | 4.30% | 1.06% | Not reported | Q3 2023 | |
| BTBCAXBicara Therapeutics Inc. | $16.9M | 3.58% | 0.86% | Not reported | Q3 2024 |
| $7.76M | 1.64% | 1.27% | Not reported | Q3 2025 | |
| $4.24M | 0.90% | 0.06% | Not reported | Q3 2025 | |
| $3.97M | 0.84% | 0.22% | Not reported | Q4 2025 | |
| $3.01M | 0.64% | 2.83% | Not reported | Q2 2021 | |
| $2.3M | 0.49% | 0.31% | Not reported | Q4 2018 | |
| $2.15M | 0.46% | 0.63% | Not reported | Q1 2026 | |
| $1.88M | 0.40% | Not reported | New | Q2 2026 | |
| $478K | 0.10% | 1.95% | Not reported | Q4 2018 | |
| $404K | 0.09% | 0.22% | Not reported | Q4 2024 | |
| Q1 2026Reported May 5, 202613 positions | |||||
| $378M | 79.35% | 2.60% | Not reported | Q2 2019 | |
| $30.8M | 6.46% | 1.49% | Not reported | Q1 2020 | |
| $25.6M | 5.37% | 1.84% | +5.7% | Q2 2021 | |
| BTBCAXBicara Therapeutics Inc. | $11.3M | 2.38% | 0.87% | Not reported | Q3 2024 |
| $9.11M | 1.91% | 1.27% | +80.3% | Q3 2025 | |
| $7.92M | 1.66% | 1.06% | +19.5% | Q3 2023 | |
| $3.79M | 0.80% | 0.06% | Not reported | Q3 2025 | |
| $3.13M | 0.66% | 2.83% | Not reported | Q2 2021 | |
| $2.35M | 0.49% | 0.63% | New | Q1 2026 | |
| $1.94M | 0.41% | 0.22% | Not reported | Q4 2025 | |
| $1.63M | 0.34% | 0.31% | Not reported | Q4 2018 | |
| $423K | 0.09% | 1.95% | Not reported | Q4 2018 | |
| $367K | 0.08% | 0.65% | Not reported | Q4 2024 | |
| Q4 2025Reported Feb 10, 202613 positions | |||||
| $389M | 81.29% | 2.61% | -16.4% | Q2 2019 | |
| $27.7M | 5.78% | 1.51% | Not reported | Q1 2020 | |
| $23.1M | 4.82% | 2.25% | Not reported | Q2 2021 | |
| BTBCAXBicara Therapeutics Inc. | $9.57M | 2.00% | 1.01% | Not reported | Q3 2024 |
| $8.27M | 1.73% | 1.25% | Not reported | Q3 2023 | |
| $7.07M | 1.48% | 0.71% | Not reported | Q3 2025 | |
| $3.43M | 0.72% | 3.38% | Not reported | Q1 2024 | |
| $3.39M | 0.71% | 0.07% | Not reported | Q3 2025 | |
| $2.54M | 0.53% | 2.83% | Not reported | Q2 2021 | |
| $2.53M | 0.53% | 0.22% | New | Q4 2025 | |
| $1.31M | 0.27% | 0.36% | Not reported | Q4 2018 | |
| $485K | 0.10% | 1.95% | Not reported | Q4 2018 | |
| $257K | 0.05% | 26.50% | Not reported | Q4 2024 | |
| Q3 2025Reported Nov 12, 202514 positions | |||||
| $316M | 69.29% | 3.16% | +0.4% | Q2 2019 | |
| VPVRNAVerona Pharma plc | $65.7M | 14.39% | 0.09% | Not reported | Q4 2018 |
| $20.3M | 4.44% | 1.52% | Not reported | Q1 2020 | |
| $11M | 2.40% | 0.88% | +16.5% | Q1 2021 | |
| $10.9M | 2.39% | 2.38% | Not reported | Q2 2021 | |
| BTBCAXBicara Therapeutics Inc. | $8.98M | 1.97% | 1.04% | Not reported | Q3 2024 |
| $6.87M | 1.50% | 1.25% | Not reported | Q3 2023 | |
| $6.54M | 1.43% | 0.71% | New | Q3 2025 | |
| $4.14M | 0.91% | 3.44% | Not reported | Q2 2021 | |
| $2.87M | 0.63% | 0.08% | New | Q3 2025 | |
| $1.6M | 0.35% | 3.66% | Not reported | Q1 2024 | |
| $825K | 0.18% | 0.40% | Not reported | Q4 2018 | |
| $290K | 0.06% | 1.95% | Not reported | Q4 2018 | |
| $244K | 0.05% | 26.50% | Not reported | Q4 2024 | |
Premium opens every quarter this fund has filed